Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Medical Devices

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Revenue projections:

Revenue projections for ABT
Revenue projections for ABT

ABT's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.

Financial Ratios:

currentRatio 1.388000
forwardPE 14.000775
debtToEquity 64.773000
earningsGrowth -0.197000
revenueGrowth 0.078000
grossMargins 0.565030
operatingMargins 0.134720
trailingEps 3.570000
forwardEps 6.063950

ABT's current ratio, being 1.388, demonstrates that the company has the liquidity necessary to service its short-term debt. With strong cash reserves and current assets, ABT is well-equipped to meet its immediate financial obligations without any difficulties.
ABT's Forward PE ratio suggests that the stock is priced appropriately in relation to its earnings. Not being overpriced, it offers room for growth, signaling potential upside for investors looking for a stock with reasonable valuation and growth potential.
ABT's low earnings and revenue growth suggest that the company may see declining profits. This indicates potential financial challenges ahead, and could lead to a more cautious outlook from investors.
ABT's negative gross and operating margins point to financial difficulties, as the company is incurring losses at both the production and operational levels. This suggests a potential decline in profitability and raises concerns about its financial outlook.
ABT's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that ABT is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for ABT
Price projections for ABT

The current valuation of ABT against its projections does not reveal significant risks or opportunities. This neutral assessment implies a stable market, where investors may prefer to maintain their positions until future trends become clearer.

Insider Transactions:

Insider Transactions for ABT
Insider Transactions for ABT


There were 5 ABT sales transactions, at market price of 128.86800079345704.There were 4 buy transactions of Abbott Laboratories, with market price at 100.22500038146973.The insider transaction data does not present a strong trend, leaving ambiguity about the company’s overall strategic or financial direction.

Recommendation changes over time:

Recommendations trend for ABT
Recommendations trend for ABT


The recent buy bias for Abbott Laboratories from analysts signals strong confidence in the stock's potential. This positive sentiment could encourage investors to see Abbott Laboratories as a smart place to invest their money, especially those looking for stable, long-term returns in a well-established company.